Cover Image

Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial

Objective: Conversion therapy (surgical resection after chemotherapy) is a promising option for unresectable gastric cancer (GC) patients. Addition of anti-angiogenesis drug improves response to chemotherapy. Hence, this study explored the feasibility and efficacy of preoperative paclitaxel (PTX)/S1...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhiyuan Xu (Author), Can Hu (Author), Jianfa Yu (Author), Yian Du (Author), Ping Hu (Author), Guofa Yu (Author), Conggang Hu (Author), Yu Zhang (Author), Wei Mao (Author), Shanqi Chen (Author), Xiangdong Cheng (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
by: Shengya Fu, et al.
Published: (2022)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2020)

Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2021)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
by: Guohu Han, et al.
Published: (2023)

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
by: Zhuangzhuang Zheng, et al.
Published: (2022)

PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis
by: Wang F, et al.
Published: (2022)

CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
by: Zhize Ye, et al.
Published: (2022)

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review
by: Dingyi Jiang, et al.
Published: (2020)

Apatinib treatment is effective for metastatic malignant phyllodes tumors of the breast: a case report
by: Xiaolu Wang, et al.
Published: (2021)

Hyaluronic acid reduction-sensitive polymeric micelles achieving co-delivery of tumor-targeting paclitaxel/apatinib effectively reverse cancer multidrug resistance
by: Xiaoqing Zhang, et al.
Published: (2020)

Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
by: Rene John D. Febro, et al.
Published: (2024)

Apatinib for molecular targeted therapy in tumor
by: Zhang H
Published: (2015)

Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients
by: Da Huang, et al.
Published: (2022)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
by: Yongbao Wei, et al.
Published: (2023)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
by: Hao Lin, et al.
Published: (2023)

Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors
by: Zhu YT, et al.
Published: (2020)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
by: Ma X, et al.
Published: (2020)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
by: Hongrui Liu, et al.
Published: (2021)

Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
by: Hongrui Liu, et al.
Published: (2022)

Unresectable gastrointestinal stromal tumors
by: Prema Menon, et al.
Published: (2011)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022)

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
by: Yu J, et al.
Published: (2019)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
by: Rui Meng, et al.
Published: (2022)

Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma
by: Xu H, et al.
Published: (2022)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data
by: Chengcheng Gong, et al.
Published: (2022)

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats
by: Shi-Qi Dong, et al.
Published: (2022)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
by: Hong-Hong Zhang, et al.
Published: (2022)

Impact of Ninjin'Yoeito on Fatigue in Patients Receiving Nab-Paclitaxel Plus Gemcitabine Therapy: A Prospective, Single-Arm, Phase II Open Label, Nonrandomized, Historically-Controlled Study
by: Ken-ichi Okada, MD, PhD, et al.
Published: (2020)

A novel fully covered metal stent for unresectable malignant distal biliary obstruction: results of a multicenter prospective study
by: Arata Sakai, et al.
Published: (2024)

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
by: Zhenyun Yang, et al.
Published: (2023)

Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report
by: Wu Y, et al.
Published: (2023)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021)

Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment
by: Yudai Fujiwara, et al.
Published: (2024)

Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial
by: Fushida S, et al.
Published: (2016)

Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis
by: Yiwen Zhou, et al.
Published: (2024)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
by: Kunlun Wang, et al.
Published: (2020)